Da Cao

Da Cao

Auto-generated profile, based on publicly available information

Da Cao


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 August 2022 in Cellular and Molecular Neurobiology
Verified
Journal Article
Closed access
PDF file
WLWang Ling
Wang Ling
YSYuanyuan Sun
Yuanyuan Sun
FKFang Kong
Fang Kong
YJYi Jiang
Yi Jiang
MAMengmeng An
Mengmeng An
PGPing Gong
Ping Gong

23 August 2026 in Life
Verified
Journal Article
Open access
PDF file
ZWZiyang Wu
Ziyang Wu
DCDa Cao
Da Cao
CTChengchun Tang
Chengchun Tang
Frailty is highly prevalent in older patients with atrial fibrillation (AF), complicating anticoagulation decisions due to the dual elevation of both stroke and bleeding risks. This narrative review provides a framework to guide these decisions. We propose a three-step approach: (1) systematically assess frailty using a validated tool to stratify patients into risk categories; (2) translate this stratification into therapeutic choices, generally favoring direct oral anticoagulants (DOACs) over warfarin, with data suggesting a favorable bleeding profile for apixaban in frail populations, but routine switching to a DOAC should be avoided in frail patients who are stable on warfarin with good time in therapeutic range; and (3) consider specific alternatives, such as very-low-dose edoxaban, for patients with severe frailty or a prohibitive bleeding risk, while noting that this strategy should be applied within its specific regulatory and clinical context. The net clinical benefit of anticoagulation, defined as the absolute risk reduction in ischemic stroke offset by the absolute risk increase in major bleeding, diminishes with increasing frailty severity and may vanish in the most severe stages. Clinical decisions must therefore integrate dynamic frailty reassessment, multidisciplinary collaboration, and patient preferences. This review underscores a shift from purely guideline-driven to patient-value-driven individualized anticoagulation strategies in frail older adults with AF.